Article | October 7, 2016

Fighting The Commoditization Of Sites: It Starts With The Site Initiation Visit (SIV)

Source: Oracle Health Sciences
Fighting The Commoditization Of Sites: It Starts With The Site Initiation Visit (SIV)

By Sujay Jadhav, CEO, goBalto

Despite advancements in clinical research technology over the last decade, recent research from the Tufts Center for the Study of Drug Development (CSDD) suggests that we are not conducting site activation any faster today than we did 20 years ago . One of the biggest factors contributing to lengthy cycle times is the inability of sponsors and Contract Research Organizations (CROs) to engage investigative sites in a manner that supports effective patient recruitment and retention in the context of a swift budget and contract process. In this mentality, the site is treated less like a valued partner and more like a commodity in the clinical research lifecycle. Want to move towards better engagement models? It starts with the Site Initiation Visit (SIV), a critical event that sets the stage for an open, collaborative relationship to last throughout the study. An initiation visit is imperative to the overall success of a study as many crucial tasks are accomplished during these visits.